The current registered CAR-T cell formulations involve four CD19-targeting products used in the treatment of B-cell-derived acute leukemias and aggressive lymphomas, and one compound targeting B-cell maturation antigen (BCMA) used in MM treatment (Table 1). The gene discussed is TNFRSF17; the disease is Miyoshi myopathy.